Quick COVID-19 Healers Sustain Anti-SARS-CoV-2 Antibody Production

• Published in: Cell Vol. 183; no. 6; pp. 1496 - 1507.e16
• Main Authors: Chen, Yuezhou, Zuiani, Adam, Fischinger, Stephanie, Mullur, Jyotsna, Atyeo, Caroline, Travers, Meghan, Lelis, Felipe J.N., Pullen, Krista M., Martin, Hannah, Tong, Pei, Gautam, Avneesh, Habibi, Shaghayegh, Bensko, Jillian, Gakpo, Deborah, Feldman, Jared, Hauser, Blake M., Caradonna, Timothy M., Cai, Yongfei, Burke, John S., Lin, Junrui, Lederer, James A., Lam, Evan Christopher, Lavine, Christy L., Seaman, Michael S., Chen, Bing, Schmidt, Aaron G., Balazs, Alejandro Benjamin, Lauffenburger, Douglas A., Alter, Galit, Wesemann, Duane R.
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 10.12.2020
• Subjects: antibodies; Antibodies, Viral - immunology; Antibody Formation; B-lymphocytes; CD4-Positive T-Lymphocytes - immunology; COVID-19; COVID-19 - genetics; COVID-19 - immunology; COVID-19 infection; durability; germinal center; Humans; Immunoglobulin G - immunology; longevity; Lymphocyte Activation; Mutation; phenotype; SARS-CoV-2; SARS-CoV-2 - genetics; SARS-CoV-2 - immunology; serology; Severe acute respiratory syndrome coronavirus 2; severity; SHM; somatic hypermutation; symptom duration; COVID-19; severity; SARS-CoV-2; somatic hypermutation; symptom duration; serology; durability; SHM; germinal center

Antibodies are key immune effectors that confer protection against pathogenic threats. The nature and longevity of the antibody response to SARS-CoV-2 infection are not well defined. We charted longitudinal antibody responses to SARS-CoV-2 in 92 subjects after symptomatic COVID-19. Antibody response...